Table 2.
Analysis of Risk Factors Comparing Patients with IFI to patients without IFI
| Patient Characteristic—n (%) | Proven/Probable IFIΘ |
No IFI N = 80 |
Odds Ratio (95% CI) |
|---|---|---|---|
| ≥ 3 prior lines of therapy | 5 (25) α | 5 (6) | 5.36 (1.25-23.03) |
| Prior alemtuzumab | 1 (5)α | 4 (5) | 1.00 (0.11-8.95) |
| Prior fludarabine | 8 (40) α | 24 (30) | 1.63 (0.56-4.76) |
| Diabetes | 4 (20) α | 11 (14) | 1.50 (0.45-4.96) |
| Glucocorticoid useμ | 2 (10) α | 2 (3) | 4.00 (0.56-28.40) |
| Prior cytotoxic chemotherapyτ | 1 (5) α | 2 (3) | 2.00 (0.18-22.06) |
| Combination therapy for CLL | 9 (45) α | 38 (48) | 0.97 (0.81-1.16) |
| Hypoalbuminemia | 10 (53) δ π | 4 (5) ε | 17.70 (3.84-81.46) |
| Neutropenia | 3 (16)δπ | 10 (13)ε | 1.26 (0.29-5.39) |
| Lymphopenia | 6 (32)δπ | 29 (36)ε | 0.79 (0.27-2.32) |
| Monocytopenia | 5 (26) δ π | 4 (5) ε | 6.00 (1.41-25.45) |
| Hypogammaglobulinemia | 8 (47)Γ | 37 (46)ε | 1.00 (0.35-2.88) |
Hypoalbuminemia = albumin < 3 g/dL; Neutropenia = < 500 cells/m3; Lymphopenia = < 1000 cells/m3; Monocytopenia = < 80 cells/m3
Θ
Patients without adequate laboratory values or follow up data within 30 days of IFI diagnosis were not included in the analysis
μ
Defined as use of ≥20 mg/day for ≥ 14 days within 3 months prior to IFI diagnosis
τ
For treatment of prior malignancy other than CLL
α
N = 20
δ
N = 19
Γ
N = 17
π
Within 30 days of IFI diagnosis
ε
at any time while on ibrutinib therapy